tiprankstipranks
Blurbs

Analysts Offer Insights on Technology Companies: Monolithic Power (MPWR), Stem Inc (STEM) and Pacific Biosciences (PACB)

There’s a lot to be optimistic about in the Technology sector as 3 analysts just weighed in on Monolithic Power (MPWRResearch Report), Stem Inc (STEMResearch Report) and Pacific Biosciences (PACBResearch Report) with bullish sentiments.

Monolithic Power (MPWR)

TD Cowen analyst Matt Ramsay reiterated a Buy rating on Monolithic Power yesterday and set a price target of $550.00. The company’s shares closed last Monday at $404.00.

According to TipRanks.com, Ramsay is a top 25 analyst with an average return of 26.1% and a 63.2% success rate. Ramsay covers the Technology sector, focusing on stocks such as MACOM Technology Solutions Holdings, Credo Technology Group Holding Ltd, and Advanced Micro Devices.

Monolithic Power has an analyst consensus of Strong Buy, with a price target consensus of $562.86, a 40.7% upside from current levels. In a report issued on October 23, Wells Fargo also maintained a Buy rating on the stock with a $575.00 price target.

See the top stocks recommended by analysts >>

Stem Inc (STEM)

TD Cowen analyst Thomas Boyes maintained a Buy rating on Stem Inc yesterday and set a price target of $7.00. The company’s shares closed last Monday at $3.16, close to its 52-week low of $3.00.

According to TipRanks.com, Boyes is ranked #8323 out of 8565 analysts.

Currently, the analyst consensus on Stem Inc is a Moderate Buy with an average price target of $8.93.

Pacific Biosciences (PACB)

In a report released yesterday, Daniel Brennan from TD Cowen maintained a Buy rating on Pacific Biosciences, with a price target of $19.00. The company’s shares closed last Monday at $7.11, close to its 52-week low of $6.70.

According to TipRanks.com, Brennan is a 1-star analyst with an average return of -4.1% and a 43.9% success rate. Brennan covers the Healthcare sector, focusing on stocks such as MDxHealth S.A. Sponsored ADR, Thermo Fisher, and Danaher.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pacific Biosciences with a $12.56 average price target, implying a 74.0% upside from current levels. In a report issued on October 17, Goldman Sachs also maintained a Buy rating on the stock with a $11.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MPWR:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles